Its main limitations as a biomarker in immunotherapy are the variability between immunohistological techniques making standardization difficult, the tumor constitutive expression of PD-L1 driven by different mechanisms independent of the adaptive response to tumor immunity and TIL assessment. This evidence concerns the gene CD274 and neoplasm.